Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just think what's going to happen when ibs reader drops
Flying over in states .
Sng take 2
and that could be just the start to the day ;)
Could see 80p tomorrow at this rate
4D Pharma and Seres operate in the same space along with a few other compan ies. Livebiotherapeutics in the microbiome.
Look at P19 in this prestation and it shows the respective market caps for the key players in the sector. 4D are generally recognised as the leader in the field and the Seres success today is a massive plus for the therapies, giving enormous credibility going forward. It has added over a billion to the Seres mkt cap and we are still way below £100 million with a series of trial results due.
https://www.4dpharmaplc.com/application/files/9815/9482/4216/4D_pharma_Management_presentation_July_2020_FINAL_web.pdf
4D are in the same game and probably more advanced. Today's news helps to prove what 4D are working on is very likely going to work and is the way forward in future pharmaceutical development . 4D has the potential to be a multi billion £ company.
Two separate fishing & chips shop. Now one discovered a new recipe.
What has Seres got to do with 4D? Please explain.
Taff thats exactly what i am saying i havealready had my 5bag from SNG missed the rise on TILS.
Plan is ODX then DDDD. ;-)
Imac1, would say 4d has more potential from here than sng and Tils, with mkt cap only £80m,no brainer it sit and wait for 5bgs easy.
Taff was in Tils twice but was trading between ODX, TILS, GDR with an eye on SNG. Was in Tils late at 81p sold at 75p :-( only to move it into ODX and then watch TILS rocket off towards 200p+ could have caught the wave but seen better near term gains from ODX or SNG. Glad i moved to SNG though cant catch them all unless diversifying the portfolio and still see ODX doing x3 bag from current price. Hopefully DDDD keeps the brakes on just a bit longer so i can get profits moved across may take a small holding for now.
Imac1, same here sold@198,was in tils@47p but sold for peanuts, not goi g to sell here u der £2min.
Taff waiting for ODX to go first then will be in here like a shot. Same boat as you with SNG was lucky yo get in on the pullback to 35-40p just before news. I had been following them closely after a recommendation on the ODX board around April/May sometime and was sweating about moving money from ODX thank goodness i did 5 bag and sold out at 200p.
Market Summary > Seres Therapeutics Inc
NASDAQ: MCRB
19.41 USD +14.77 (318.32%)
WOWSA !!!
Sees up335% $1b mkt cap, wakey wakey everyone
It’s unbelievable the disconnect between market caps of both companies when comparing pipeline, they have 2 therapy’s in Phase trials and 4 in Pre-clinical!
4d has 5 in Phase trials and 3 in Pre-clinical!
https://imgur.com/a/hGdvDJP
Massive news coming here and it will be factual this time .
No speeding ticket.
So all.bets off how high this goes
In 2016 $MCRB had a 'bad' Phase II Clinical Trial result on their c.difficile product. Today they've had positive news on a Phase III trial on the same indication.
2016 'Fail' led to huge de-rating of the entire Microbiome sector. Today's news should see MAJOR re-rating #DDDD
Mickle, have a look at PDSB aswell tiny mkt cap huge potential, covid19 vaccine play with 2 vaccines, also in bed with Merck.
But we have no connection with seres. Hope they would take us over
Series up 300% pre market valued close to $1b,4d £80m mmmmmm
lol Im gutted as I came out of Seres last week at a small profit, great result for them!
here's hoping for the same here GLA
“We are extremely pleased with these highly clinically meaningful SER-109 Phase 3 study results, greatly exceeding the statistical threshold provided by the FDA. Based on our prior discussions with the FDA, we believe this trial should provide the efficacy basis for submitting an application for product approval. We look forward to meeting with the FDA as soon as possible to discuss the regulatory path forward with the goal of bringing SER-109 to patients as a first-in-class microbiome therapeutic,” said Eric D. Shaff, President and Chief Executive Officer of Seres. “Our results represent the first-ever positive pivotal clinical study results for a targeted microbiome drug candidate. We believe these Phase 3 data provide strong validation for our underlying microbiome therapeutics platform, which has been the scientific basis for the Company, as well as persuasive clinical evidence supporting our other active pipeline programs.”
“We would like to thank all those who participated in this landmark study. Based on these highly positive SER-109 ECOSPOR III results, we believe that this novel microbiome therapeutic candidate could potentially provide a much-needed effective oral treatment option for the approximately 170,000 patients in the U.S. that suffer from recurrent CDI annually,” said Lisa von Moltke, M.D., FCP, Chief Medical Officer of Seres. “Seres applied a data-driven and scientifically rigorous approach to develop SER-109. The proprietary scientific learnings we have obtained continue to drive our overall R&D efforts and the advancement of our other ongoing microbiome therapeutic programs.“
https://ir.serestherapeutics.com/node/9421/pdf
Hold Guys only going one way!
https://twitter.com/davidburton1971/status/1292791748108980224?s=21